...
首页> 外文期刊>Experimental Eye Research >Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In?vitro and ex?vivo functionality studies in corneal epithelial cells
【24h】

Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In?vitro and ex?vivo functionality studies in corneal epithelial cells

机译:新型抗炎脂质体制剂用于前眼泪膜:在角膜上皮细胞中的体外和EX?体内功能研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract In ocular surface inflammatory diseases, such as dry eye disease, long-term symptom relief requires targeting the inflammation itself rather than treating only the surface-associated dryness with artificial tears. Therefore, we included an anti-inflammatory agent in an unpreserved liposome-based (LP) formulation used as artificial tears. Our aim was to characterize and study its in?vitro and ex?vivo cell uptake and functionality. Human corneal epithelial (HCE) cells were used to study MPA-LP-induced effects after 60?min of exposure, using blank LP and non-LP MPA formulations as controls. A fluorescent labeled LP formulation was used to determine uptake by HCE cells and localization in ex?vivo porcine corneas. The LP formulation complied with the required physicochemical properties and had no cytotoxicity on HCE cells after 60?min of exposure. HCE cells showed LP-associated fluorescence at 24, 48, and 72?h after 60?min of exposure, and the LP-associated fluorescence was uniformly distributed throughout the porcine corneal epithelium immediately after 5?min of exposure. MPA-LP increased protein expression and nuclear translocation of progesterone receptor in comparison with controls as determined by Western blotting and immunofluorescence. Moreover, MPA-LP significantly reduced the cell proliferation rate and IL-6 and IL-8 production 48?h after the exposure period, as determined by the alamarBlue assay and ELISA, respectively. None of these effects were evident in blank LP-exposed cells and non-LP MPA formulation reduced only IL-6 production. Our results suggest that the LP-based formulation, used to replenish the lipids of the tear film, can be loaded with anti-inflammatory agents that can be delivered into the cells and activate specific drug receptors. These agents can reduce inflammatory cytokine production and may be effective in the treatment of inflammatory processes associated with ocular surface diseases. Graphical abstract Display Omitted Highlights ? Medroxyprogesterone was incorporated into a liposomal artificial tear formulation. ? Encapsulated drug readily penetrates corneal tissue in an ex?vivo porcine model. ? Encapsulated drug exerts anti-inflammatory effects in human corneal cells in?vitro . ? The novel liposomal artificial tears enhance the effect of the drug in?vitro .
机译:摘要在眼表面炎症疾病(如干眼症,长期症状浮雕需要靶向炎症本身,而不是用人工泪液治疗表面相关的干燥度。因此,我们包括在未验证的脂质体(LP)制剂中的抗炎剂,用作人造泪液。我们的目的是表征和研究其在体外和ex?体内细胞摄取和功能。使用空白LP和非LP MPA制剂作为对照,使用空白LP和非LP MPA制剂在60?min之后研究人体角膜上皮(HCE)细胞研究MPa-LP诱导的效果。使用荧光标记的LP制剂来确定通过HCE细胞的摄取和在前磷酸中的局部化。 LP制剂符合所需的物理化学特性,并且在60℃暴露后的HCE细胞上没有细胞毒性。 HCE细胞在暴露60?min后24,48和72℃下显示出LP相关的荧光,并且在暴露5?min之后立即将LP相关的荧光均匀地分布在整个猪角膜上皮中。与通过蛋白质印迹和免疫荧光测定的对照相比,MPA-LP增加了孕酮受体的蛋白质表达和核易位。此外,MPa-LP分别在暴露期之后显着降低了细胞增殖率和IL-6和IL-8产生48ΩH,分别由Alamarblue测定和ELISA确定。在空白的LP暴露细胞中没有任何这些效果是明显的,并且非LP MPA制剂仅减少IL-6生产。我们的研究结果表明,用于补充撕裂膜的脂质的基于LP的制剂可以用可以递送到细胞中并激活特异性药物受体的抗炎剂。这些药剂可以降低炎症细胞因子产生,并且可以有效地治疗与眼部疾病相关的炎症过程。图形抽象显示省略了亮点?将Medroxyprogertone掺入脂质体人工撕裂制剂中。还包封的药物容易穿透EXα体内猪模型中的角膜组织。还包封的药物在人角膜细胞中发挥抗炎作用。还新型脂质体人工泪液增强了药物在体外的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号